Stocks and Investing Stocks and Investing
Wed, August 28, 2024

Hartaj Singh Maintained (UTHR) at Buy with Increased Target to $575 on, Aug 28th, 2024


Published on 2024-10-28 13:56:23 - WOPRAI, Hartaj Singh
  Print publication without navigation


Hartaj Singh of Oppenheimer, Maintained "United Therapeutics Corporation" (UTHR) at Buy with Increased Target from $400 to $575 on, Aug 28th, 2024.

Hartaj has made no other calls on UTHR in the last 4 months.



There are 8 other peers that have a rating on UTHR. Out of the 8 peers that are also analyzing UTHR, 2 agree with Hartaj's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Terence Flynn of "Morgan Stanley" Downgraded from Buy to Hold and Increased Target to $321 on, Thursday, July 11th, 2024
  • Chris Shibutani of "Goldman Sachs" Maintained at Hold with Increased Target to $240 on, Friday, May 3rd, 2024


These are the ratings of the 6 analyists that currently disagree with Hartaj


  • Tiago Fauth of "Wells Fargo" Maintained at Buy with Increased Target to $380 on, Tuesday, August 20th, 2024
  • Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $400 on, Thursday, August 1st, 2024
  • Greg Harrison of "B of A Securities" Maintained at Sell with Decreased Target to $280 on, Thursday, August 1st, 2024
  • Joseph Thome of "TD Cowen" Maintained at Strong Buy with Increased Target to $350 on, Thursday, July 11th, 2024
  • Ashwani Verma of "UBS" Maintained at Strong Buy with Increased Target to $370 on, Monday, July 8th, 2024
  • Jessica Fye of "JP Morgan" Maintained at Buy with Increased Target to $300 on, Tuesday, May 21st, 2024
Contributing Sources